These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34038857)

  • 21. A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
    Pflug A; Schimpl M; Nissink JWM; Overman RC; Rawlins PB; Truman C; Underwood E; Warwicker J; Winter-Holt J; McCoull W
    Biochem J; 2020 Nov; 477(22):4443-4452. PubMed ID: 33119085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UNC569-induced Morphological Changes in Pigment Epithelia and Photoreceptor Cells in the Retina through MerTK Inhibition in Mice.
    Sayama A; Okado K; Nakamura K; Kawaguchi T; Iguchi T; Makino T; Yabe K; Kai K; Mori K
    Toxicol Pathol; 2018 Feb; 46(2):193-201. PubMed ID: 29310530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
    Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
    Front Immunol; 2020; 11():564133. PubMed ID: 33101282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MERTK is a host factor that promotes classical swine fever virus entry and antagonizes innate immune response in PK-15 cells.
    Zheng G; Li LF; Zhang Y; Qu L; Wang W; Li M; Yu S; Zhou M; Luo Y; Sun Y; Munir M; Li S; Qiu HJ
    Emerg Microbes Infect; 2020; 9(1):571-581. PubMed ID: 32172658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.
    Eom H; Kaushik N; Yoo KC; Shim JK; Kwon M; Choi MY; Yoon T; Kang SG; Lee SJ
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):87-95. PubMed ID: 29553850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MerTK as a therapeutic target in glioblastoma.
    Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
    Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.
    Crittenden MR; Baird J; Friedman D; Savage T; Uhde L; Alice A; Cottam B; Young K; Newell P; Nguyen C; Bambina S; Kramer G; Akporiaye E; Malecka A; Jackson A; Gough MJ
    Oncotarget; 2016 Nov; 7(48):78653-78666. PubMed ID: 27602953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulforaphane rescues amyloid-β peptide-mediated decrease in MerTK expression through its anti-inflammatory effect in human THP-1 macrophages.
    Jhang KA; Park JS; Kim HS; Chong YH
    J Neuroinflammation; 2018 Mar; 15(1):75. PubMed ID: 29530050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MERTK Acts as a Costimulatory Receptor on Human CD8
    Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
    Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
    Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
    Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
    Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
    Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
    Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dead Cells Induce Innate Anergy via Mertk after Acute Viral Infection.
    Adomati T; Cham LB; Hamdan TA; Bhat H; Duhan V; Li F; Ali M; Lang E; Huang A; Naser E; Khairnar V; Friedrich SK; Lang J; Friebus-Kardash J; Bergerhausen M; Schiller M; Machlah YM; Lang F; Häussinger D; Ferencik S; Hardt C; Lang PA; Lang KS
    Cell Rep; 2020 Mar; 30(11):3671-3681.e5. PubMed ID: 32187540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
    Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
    J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Oncogenic Effect of the MERTK-Dependent Apoptotic-Cell Clearance Pathway in Starry-Sky B-Cell Lymphoma.
    Farnworth-McHugh S; Barth N; Melville L; Paterson M; Lynch C; Holland P; Dransfield I; Gregory C
    Front Immunol; 2020; 11():1759. PubMed ID: 32973744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DBA/2J Haplotype on Distal Chromosome 2 Reduces Mertk Expression, Restricts Efferocytosis, and Increases Susceptibility to Atherosclerosis.
    Kayashima Y; Makhanova N; Maeda N
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):e82-e91. PubMed ID: 28473436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold.
    Zhou S; Zhou L; Cui R; Tian Y; Li X; You R; Zhong L
    Comb Chem High Throughput Screen; 2016; 19(1):73-96. PubMed ID: 26632441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.